Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maurizio Roveri"'
Autor:
Simon Matoori, Maurizio Roveri, Peter Tiefenboeck, Annatina Romagna, Olha Wuerthinger, Orpheus Kolokythas, Johannes M. Froehlich
Publikováno v:
European Radiology Experimental, Vol 3, Iss 1, Pp 1-11 (2019)
Abstract Background Externally controlling and monitoring drug release at a desired time and location is currently lacking in the gastrointestinal tract. The aim of the study was to develop a thermoresponsive wax-coated capsule and to trigger its rel
Externí odkaz:
https://doaj.org/article/e8034c83857745fda6b3a6cf431f7b29
Autor:
Zelia L Gouveia, Sandrine Moutel, Beat W. Schäfer, Franck Perez, Gianmarco Meier, Nagjie Alijaj, Michele Bernasconi, Maurizio Roveri, Paola Luciani, Jochen Rössler, Maxim Gray, Florian Weber, Dzhangar Dzhumashev
Publikováno v:
Cancers, Vol 12, Iss 3313, p 3313 (2020)
Cancers
Alijaj, Nagjie; Moutel, Sandrine; Gouveia, Zelia L; Gray, Maxim; Roveri, Maurizio; Dzhumashev, Dzhangar; Weber, Florian; Meier, Gianmarco; Luciani, Paola; Rössler, Jochen K.; Schäfer, Beat W; Perez, Franck; Bernasconi, Michele (2020). Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma. Cancers, 12(11) MDPI AG 10.3390/cancers12113313
Volume 12
Issue 11
Cancers
Alijaj, Nagjie; Moutel, Sandrine; Gouveia, Zelia L; Gray, Maxim; Roveri, Maurizio; Dzhumashev, Dzhangar; Weber, Florian; Meier, Gianmarco; Luciani, Paola; Rössler, Jochen K.; Schäfer, Beat W; Perez, Franck; Bernasconi, Michele (2020). Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma. Cancers, 12(11) MDPI AG 10.3390/cancers12113313
Volume 12
Issue 11
Simple Summary Rhabdomyosarcoma (RMS) accounts for more than 50% of all soft tissue sarcomas in childhood and adolescence. Despite progress and intensified multimodality treatment, prognoses are extremely poor with an overall survival rate of approxi
Publikováno v:
Journal of materials chemistry. B. 5(23)
Important elements for an efficient tumor targeted delivery are cancer-specific de novo- or over-expression of target receptors and their availability on the tumor cell surface. Peptides can be designed to selectively bind to such receptors and act a
Autor:
Maurizio Roveri, Simon Matoori, Peter Tiefenboeck, Olha Wuerthinger, Annatina Romagna, Orpheus Kolokythas, Johannes M. Froehlich
Publikováno v:
European Radiology Experimental, Vol 3, Iss 1, Pp 1-11 (2019)
European Radiology Experimental
European Radiology Experimental, 3 (1)
European Radiology Experimental
European Radiology Experimental, 3 (1)
Background Externally controlling and monitoring drug release at a desired time and location is currently lacking in the gastrointestinal tract. The aim of the study was to develop a thermoresponsive wax-coated capsule and to trigger its release upon
Autor:
Nagjie Alijaj, Patricia Jaaks, Maurizio Roveri, Alice Pfohl, Michele Bernasconi, Jean-Christophe Leroux, Paola Luciani
Publikováno v:
Nanomedicine (London, England). 12(10)
Aim: Our goal was to improve vincristine (VCR) based rhabdomyosarcoma (RMS) therapy by encapsulating the drug into liposomes. A targeting strategy was attempted to enhance tumor accumulation. Materials & methods: VCR was loaded in control and peptide
Autor:
Gabriele Manzella, Maurizio Roveri, Nagjie Alijaj, Marco Wachtel, Maxim Gray, Sandrine Moutel, Michele Bernasconi, Beat W. Schäfer, Franck Perez
Publikováno v:
Cancer Research. 79:3116-3116
Rhabdomyosarcoma (RMS) is an aggressive pediatric soft tissue sarcoma and is classified into two main histopathological subtypes: embryonal RMS (eRMS), characterized by different genomic changes or alveolar RMS (aRMS), driven by the oncogenic fusion
Autor:
Bruno Gander, Monika Håkerud, Vera Vonwil, Maurizio Roveri, Céline Bühler, Ying Wäckerle-Men, Pål Johansen, Ásdís Hjálmsdóttir
Publikováno v:
Molecular pharmaceutics. 13(2)
One of the greatest pharmaceutical challenges in vaccinology is the delivery of antigens to the cytosol of antigen-presenting cells (APCs) in order to allow for the stimulation of major histocompatibility complex (MHC) class I-restricted CD8(+) T-cel
Publikováno v:
Science translational medicine. 6(258)
Peritoneal dialysis confers therapeutic advantages in patients with renal insufficiency and has proven beneficial in other indications, such as removal of excess metabolites or overdosed drugs. However, it is used in only about 10% of the dialyzed po